Metastatic Gastroesophageal Junction Adenocarcinoma

DrugDrug NameDrug Description
DB00072TrastuzumabA recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein. Produced in CHO cell culture. In December 2017, FDA approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). It displays biosimilar properties as Herceptin according to clinical data. While Ogivri is the first biosimilar approved in the U.S. for the treatment of breast cancer or stomach cancer, it is the second biosimilar approved in the U.S. for the treatment of cancer.
DrugDrug NamePhaseStatusCount
DB12413Indusatumab vedotin1 / 2Completed1
DB00762Irinotecan1 / 2Not Yet Recruiting1
DB05578Ramucirumab1 / 2Not Yet Recruiting1
DB11794Berzosertib2Not Yet Recruiting1
DB00762Irinotecan2Not Yet Recruiting1